Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 1

Status

Completed 5Recruiting 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Tumor-Agnostic 2Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Ovarian Neoplasms 5Neoplasms 5Neoplasm Metastasis 5Fallopian Tube Neoplasms 4Carcinoma 4Carcinoma, Renal Cell 3Sarcoma 2Glioblastoma 2Gastrointestinal Neoplasms 2Colorectal Neoplasms 2Breast Neoplasms 2Brain Neoplasms 2Stomach Neoplasms 1Sarcoma, Endometrial Stromal 1Renal Insufficiency 1Rectal Neoplasms 1Prostatic Neoplasms 1Oligodendroglioma 1Melanoma 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Kidney Neoplasms 1Kidney Diseases 1Hemangiosarcoma 1Gliosarcoma 1Glioma 1Congenital Abnormalities 1

Interventions

Gemcitabine 109Paclitaxel 92Carboplatin 79pembrolizumab 75Bevacizumab 75Surveys and Questionnaires 70Docetaxel 69Cisplatin 67Nivolumab 48Exercise 48Capecitabine 48Cyclophosphamide 47Sorafenib 43Fluorouracil 43Irinotecan 42Pemetrexed 37Albumin-Bound Paclitaxel 35Radiotherapy 34Dexamethasone 34Blood Specimen Collection 34Oxaliplatin 31Leucovorin 31Erlotinib Hydrochloride 31trametinib 30130-nm albumin-bound paclitaxel 29Cetuximab 28Therapeutics 26Ipilimumab 26Standard of Care 25Methods 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × Neoplasms × trebananib × Clear all
NCT00807859 2022-11-08

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Amgen

Phase 1 Completed
65 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT00770536 2015-09-29

AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR

Amgen

Phase 1 Completed
103 enrolled
Gynecologic

Carcinoma, Fallopian Tube Neoplasms, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms

NCT02525536 2015-09-22

A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Trebananib (AMG 386 ) in Adult Japanese Participants With Advanced Solid Tumors

Takeda

Phase 1 Completed
18 enrolled 38 charts
Tumor-Agnostic

Neoplasms

NCT00752570 2015-09-02

A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma

Amgen

Phase 2 Completed
144 enrolled
Gastrointestinal

Carcinoma, Colonic Neoplasms, Gastrointestinal Neoplasms, Neoplasm Metastasis, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00102830 2010-08-20

Study Evaluating AMG 386 in Adult Patients With Advanced Solid Tumors

Amgen

Phase 1 Completed
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡